Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | PFE | Common Stock | Options Exercise | $267K | +9.75K | +7.02% | $27.34 | 149K | Feb 23, 2024 | Direct | F1 |
transaction | PFE | Common Stock | Tax liability | -$12.7K | -458 | -0.31% | $27.76 | 148K | Feb 23, 2024 | Direct | F2 |
transaction | PFE | Common Stock | Tax liability | -$18.7K | -675 | -0.46% | $27.76 | 148K | Feb 23, 2024 | Direct | F3 |
transaction | PFE | Common Stock | Tax liability | -$216K | -7.88K | -5.34% | $27.37 | 140K | Feb 23, 2024 | Direct | F4, F5 |
transaction | PFE | Common Stock | Tax liability | -$8.33K | -300 | -0.21% | $27.76 | 139K | Feb 24, 2024 | Direct | F2, F6 |
transaction | PFE | Common Stock | Award | $0 | +15.5K | +11.09% | $0.00 | 155K | Feb 25, 2024 | Direct | F7 |
transaction | PFE | Common Stock | Tax liability | -$38.9K | -1.4K | -0.91% | $27.76 | 153K | Feb 25, 2024 | Direct | F2, F6 |
transaction | PFE | Common Stock | Tax liability | -$133K | -4.79K | -3.12% | $27.76 | 149K | Feb 25, 2024 | Direct | F6, F8 |
holding | PFE | Common Stock | 624 | Feb 23, 2024 | By Rule 16b-3 Plan |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | PFE | Stock Appreciation Rights | Options Exercise | $0 | -9.75K | -100% | $0.00* | 0 | Feb 23, 2024 | Common Stock | 9.75K | $27.34 | Direct |
Id | Content |
---|---|
F1 | The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). |
F2 | The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the vesting of restricted stock units (including dividend equivalents thereon). |
F3 | The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. |
F4 | The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). |
F5 | Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. |
F6 | Price is the closing price of Pfizer common stock on February 23, 2024. |
F7 | The reported transaction constitutes the earn-out of performance share awards (including dividend equivalents thereon). |
F8 | The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the earn-out of performance share awards (including dividend equivalents thereon). |